𝗟𝘂𝗺𝗶𝗻𝗮𝗿𝘆 𝗚𝗿𝗼𝘂𝗽, 𝗚𝗹𝗼𝗯𝗮𝗹 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝗰𝘆 #artificialintelligence #realworlddata #mergersandacquisitions #realworldevidence #productlifecycle #regulatory #pharmacovigilence #bioprocessing #cdmo #clinicaltrials #consultancy #eclinical #saas #ecoa
About us
Luminary Group, headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, is an international executive search and business consultancy specializing in the Life Sciences and Pharmaceutical sectors. Our expertise lies within the Real World Evidence, eClinical, Artificial Intelligence, Consulting and Biotechnology disciplines with localized insights and specialized knowledge. Executive Search - Tailored executive search solutions to identify and recruit top talent for key leadership positions ranging from Chairman, Board, CEO, CCO, COO, CPO - AVP Design and Recruitment for Commercial Team Organization -Strategic planning and talent acquisition services to build high-performing commercial teams aligned with business goals. Design and Recruitment for Operations Team Organization -Expert guidance in structuring and staffing operations teams for efficient and effective business operations. Data Partnerships, Business Partnerships and M&A Consulting -Advisory assistance in forging data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe. Additionally, we aid in cultivating business collaborations with biotechnology firms and guiding through mergers and acquisitions to foster growth and innovation. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our exclusive partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from Corporate to innovative Start-Ups. For additional details, please explore our website: www.luminarygroup.co.uk
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
City of London , GB
Employees at Luminary Group
Updates
-
𝗘𝗨 𝗽𝗮𝗻𝗲𝗹 𝗳𝗼𝗹𝗹𝗼𝘄𝘀 𝗙𝗗𝗔’𝘀 𝗹𝗲𝗮𝗱 𝗼𝗻 𝗪𝗲𝗴𝗼𝘃𝘆, 𝗿𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝗶𝗻𝗴 𝘂𝘀𝗲 𝘁𝗼 𝗽𝗿𝗲𝘃𝗲𝗻𝘁 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝗲𝘃𝗲𝗻𝘁𝘀 European Renal Association (ERA) regulators are poised to approve Novo Nordisk blockbuster drug Buy Wegovy to reduce the risk of cardiovascular events in patients who are overweight or obese … https://lnkd.in/d3ZirRAr
-
𝗖𝗮𝗹𝗹𝗶𝗱𝗶𝘁𝗮𝘀 𝗰𝗹𝗮𝗶𝗺𝘀 𝗺𝗶𝗱-𝘀𝘁𝗮𝗴𝗲 𝘄𝗶𝗻 𝗳𝗼𝗿 𝗿𝗮𝗿𝗲 𝗹𝗶𝘃𝗲𝗿 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗱𝗿𝘂𝗴 Calliditas Therapeutics NOX enzyme inhibitor succeeded in a Phase 2b trial in people with a rare liver disease that features inflammation and injury in the …Renee Aguiar-Lucander https://lnkd.in/dhYnTqdP
Calliditas claims mid-stage win for rare liver disease drug
https://endpts.com
-
𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮 𝗱𝗲𝘁𝗮𝗶𝗹𝘀 ‘𝘃𝗲𝗿𝘆 𝗮𝗺𝗯𝗶𝘁𝗶𝗼𝘂𝘀’ 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗳𝗼𝗿 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝘀 AstraZeneca plans to develop treatment options for people with different BMIs as part of its “very ambitious” obesity strategy. AstraZeneca CEO Pascal Soriot on Thursday https://lnkd.in/dMHVp_ii
AstraZeneca details ‘very ambitious’ strategy for early-stage obesity programs
https://endpts.com
-
𝗩𝗶𝗸𝗶𝗻𝗴 𝘁𝗼 𝗽𝘂𝘀𝗵 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝗱𝗿𝘂𝗴 𝘁𝗼 𝗣𝗵𝗮𝘀𝗲 𝟯 𝗶𝗻 𝗯𝗶𝗱 𝘁𝗼 𝗿𝗲𝗮𝗰𝗵 𝗺𝗮𝗿𝗸𝗲𝘁 𝗳𝗮𝘀𝘁𝗲𝗿 Viking Therapeutics, Inc.is stepping on the gas with its experimental GLP-1/GIP receptor agonist for obesity, forgoing a Phase 2b study and jumping right into Phase …Brian Lian https://lnkd.in/drHmcdQG
Viking to push obesity drug to Phase 3 in bid to reach market faster
https://endpts.com
-
𝗦𝗮𝗻𝗼𝗳𝗶 𝗲𝘆𝗲𝘀 𝗥𝗦𝗩 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗳𝗼𝗿 𝗶𝘁𝘀 𝗻𝗲𝘅𝘁 𝗯𝗹𝗼𝗰𝗸𝗯𝘂𝘀𝘁𝗲𝗿 𝗱𝗿𝘂𝗴 𝘄𝗵𝗶𝗹𝗲 𝗗𝘂𝗽𝗶𝘅𝗲𝗻𝘁 𝗯𝗿𝗶𝗻𝗴𝘀 𝗶𝗻 𝗿𝗲𝗰𝗼𝗿𝗱 𝘀𝗮𝗹𝗲𝘀 Sanofi's RSV antibody Beyfortus® (nirsevimab-alip) is still on track to reach blockbuster status this year as the company expands manufacturing capacity… https://lnkd.in/dgibKKpc
Sanofi eyes RSV antibody for its next blockbuster drug while Dupixent brings in record sales
https://endpts.com
-
We are thrilled to announce the launch of our brand new website: www.luminarygroup.co.uk Luminary Group, is an international executive search and business consultancy specializing in the Life Sciences and Pharmaceutical sectors. Contact us today! #NewWebsite #LuminaryGroup #DigitalLaunch #ExploreNow
-
𝗜𝗽𝘀𝗲𝗻 𝗽𝗮𝘆𝘀 𝗗𝗮𝘆 𝗢𝗻𝗲 $𝟭𝟭𝟭𝗠 𝘂𝗽𝗳𝗿𝗼𝗻𝘁 𝗳𝗼𝗿 𝗲𝘅-𝗨𝗦 𝗿𝗶𝗴𝗵𝘁𝘀 𝘁𝗼 𝗽𝗲𝗱𝗶𝗮𝘁𝗿𝗶𝗰 𝗯𝗿𝗮𝗶𝗻 𝘁𝘂𝗺𝗼𝗿 𝗱𝗿𝘂𝗴 In another move to boost its oncology portfolio, Ipsen is handing Day One Biopharmaceuticals $111 million upfront so it can take the pediatric brain tumor …David Loew , Ipsen https://lnkd.in/dw-zccPr
Ipsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug
https://endpts.com
-
𝗡𝗼𝘃𝗮𝗿𝘁𝗶𝘀 𝗽𝗮𝘆𝘀 $𝟭𝟱𝟬𝗠 𝘂𝗽𝗳𝗿𝗼𝗻𝘁, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 $𝟮𝟱𝗠 𝗶𝗻 𝗲𝗾𝘂𝗶𝘁𝘆, 𝗳𝗼𝗿 𝗗𝗿𝗲𝗻 𝗕𝗶𝗼’𝘀 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝘀 Dren Bio, Inc. inked a research pact with Novartis for select myeloid engagers to treat cancer, marking its second collaboration with a large pharma. The Swiss …Nenad Tomasevic https://lnkd.in/d_vJXxEN
Novartis pays $150M upfront, including $25M in equity, for Dren Bio’s bispecifics
https://endpts.com
-
𝗣𝗳𝗶𝘇𝗲𝗿 𝘀𝗮𝘆𝘀 𝗵𝗲𝗺𝗼𝗽𝗵𝗶𝗹𝗶𝗮 𝗔 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗿𝗲𝗱𝘂𝗰𝗲𝗱 𝗯𝗹𝗲𝗲𝗱𝗶𝗻𝗴 𝗶𝗻 𝗣𝗵𝗮𝘀𝗲 𝟯 𝘀𝘁𝘂𝗱𝘆 Pfizer announced on Wednesday morning that its gene therapy for hemophilia A met its primary objective in a key clinical trial, and the company plans … https://lnkd.in/dfWGG4hR
Pfizer touts Phase 3 gene therapy data in hemophilia A, but now it needs to prove it can win the market
https://endpts.com